Chimerix Promotes Michelle LaSpaluto to Chief Financial Officer
December 04, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 24, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 24, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on November 20, 2023, the Compensation Committee of Chimerix’s Board of Directors granted an inducement...
Chimerix Strengthens Executive Leadership Team with Appointment of Thomas Riga as Chief Operating and Commercial Officer
November 16, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Reports Third Quarter 2023 Financial Results and Provides Operational Update
November 02, 2023 07:00 ET
|
Chimerix, Inc.
– Phase 3 ACTION Study Ongoing with 113 Sites Activated Across 12 Countries; Interim Survival and PFS Data on Track to Report in 2025 – – Actively Recruiting ONC206 Dose Escalation Studies;...
Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023
October 26, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix to Participate in Upcoming Investor Conferences
September 05, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
August 16, 2023 10:05 ET
|
Chimerix, Inc.
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts...
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
August 03, 2023 07:00 ET
|
Chimerix, Inc.
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in...
Chimerix to Report Second Quarter 2023 Financial Results and Provide an Operational Update on August 3, 2023
July 27, 2023 07:00 ET
|
Chimerix, Inc.
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients...
Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer
June 27, 2023 16:05 ET
|
Chimerix, Inc.
Mike Sherman to Transition to Chair of the Board of Directors Martha Demski to Assume Role of Lead Independent Director DURHAM, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Chimerix,...